Granted patents & published patent applications 

  1. Preparation of substituted phenoxyacetic acids and derivatives as ClC-​1 inhibitors for the treatment of neuromuscular disorders. Kelly, N.; Knutsen, L.J. S.; Cotton, D.P. PCT Int. Appl. (2020), WO 2020254553 A1 24 December 2020.
  2. Preparation of substituted difluoroalkyl phenoxyacetic acid derivatives and analogs as ClC-​1 inhibitors for the treatment of neuromuscular disorders. Knutsen, L.J.S.; Kelly, N.; Skov, M.B.; Riisager, A.; Saraswat, N. PCT Int. (2020), WO 2020254559 A1 24 December 2020.
  3. Preparation of 5-​[(1S)​-​1-​(4-​bromophenoxy)​ethyl]​-​2H-​tetrazole derivatives and related compounds as ClC-​1 inhibitors for the treatment of neuromuscular disorders. Knutsen, L.J.S.; Broch-Lips, M.; Cooper, M.E.; Holm Pedersen, T.; Dudekula, D.; Saraswat, N.; Taj, R.A.; Labelle, M. PCT Int. Appl. (2020), WO 2020254558 A1 24 December 2020.
  4. Compounds for the treatment of neuromuscular disorders. Knutsen, L.J.S.; Holm Pedersen, T.; Kelly, N.; Cooper, M.E.; Brown, A.W. Eur. Pat. Appl. (2020), EP 3753560 A1 23 December 2020.
  5. Preparation of substituted phenoxyacetates for the treatment of neuromuscular disorders. Knutsen, L.J.S.; Kelly, N.; Pedersen, T.H.; Cooper, M.E.; Brown, A.W. PCT Int. Appl. (2019), WO 2019115781 A1, 20 June 2019.
  6. Phenoxy acids for the treatment of neuromuscular disorders. Knutsen, L.J.S.; Kelly, N.; Pedersen, T.H.; Olesen, C.E.; Little, P.B.; Cooper, M.E.; Saraswat, N.; Dudekula, D.; Taj, R.A.; Labelle, M. PCT Int. Appl. (2019), WO 2019115780 A1, 20 June 2019.
  7. Phenoxy acids for the treatment of neuromuscular disorders. Pedersen, T.H.; Knutsen, L.J.S.; Kelly, N.; Broch-Lips, M.; Olesen, C.E.; Baekgaard Nielsen, O.; Kumar, R.; LaBelle, M. PCT Int. Appl. (2019), WO 2019115777 A1, 20 June 2019.
  8. Preparation of substituted 2-​phenoxyalkanoic acids for the treatment of neuromuscular disorders. Knutsen, L.J.S.; Cooper, M.E.; Brown, A.W. U.S. Pat. Appl. Publ. (2019), US 20190185437 A1, 20 June 2019.
  9. Preparation of 2-​phenoxyalkanoic acids for the treatment of neuromuscular disorders. Knutsen, L.J.S.; Pedersen, T.H.; Broch-Lipps, M.; Olesen, C.E.; Labelle, M.; Nielsen, O.B. U.S. Pat. Appl. Publ. (2019), US 20190183833 A1, 20 June 2019.
  10. Compounds for the treatment of neuromuscular disorders. Pedersen, T.H.; Knutsen, L.J.S.; Kelly, N.; Broch-Lipps, M.; Olesen, C.E.; Labelle, M.; Nielsen, O.B.; Kumar, R. U.S. Pat. Appl. Publ. (2019), US 20190183834 A1, 20 June 2019.
  11. Compounds for the treatment of neuromuscular disorders. Knutsen, L.J.S.; Kelly, N.M.; Pedersen, T.H.; Cooper, M.E.; Brown, A.W. U.S. Pat. Appl. Publ. (2019), US 20190183863 A1 20 June 2019.
  12. Preparation of substituted 2-​phenoxyalkanoic acids for the treatment of neuromuscular disorders. Knutsen, L.J.S.; Pedersen, T.H.; Olesen, C.E.; Labelle, M.A.; Little, P.B.; Cooper, M.E.; Saraswat, N.; Dudekula, D.; Taj, R.A. U.S. Pat. Appl. Publ. (2019), US 20190185409 A1, 20 June 2019.
  13. Antihistamines in combination with a range of substance for improved health. Knutsen, L.J.S.; Knutsen, J.L.; Pimley, M.A. (Requis Pharmaceuticals Inc.). PCT Int. Appl. (2015), WO 2015/089489 A1, 18 June 2015.
  14. Preparations for the treatment of sleep-related breathing disorders. Knutsen, L.J.S.; Hand, J.M. (Requis Pharmaceuticals Inc.). PCT Int. Appl. (2014), WO 2014/138162 A1, 12 September 2014.
  15. Method for the Treatment of Neuropathies associated with Charcot-Marie-Tooth 1A (CMT1A) Disease. Inglese, J.; Svaren, J.P. Jang, S-W.; Scheideler, M.A.; Knutsen, L.J.S. (National Institutes of Health, US Dept. of Health and Human Services and Charcot-Marie-Tooth Association) PCT Int. Appl. (2014), US 2014/0080787 A1, 20 March 2014.
  16. Pyridazinone derivatives. Bacon, E.R.; Bailey, T.R.; Becknell, N.C.; Chatterjee, S.; Dunn, D.; Hostetler, G.A.; Hudkins, R.L.; Josef, K.A.; Knutsen, L.J.S.; Tao, M.; Zulli, A.L. (Cephalon, Inc.). U.S. Pat. Appl. Publ. (2014), US 20140142088 A1, 22 May 2014.
  17. Combination nutritional and nutraceutical products.  Knutsen, J.L.; Knutsen, L.J.S. (Requis Pharmaceuticals Inc.). PCT Int. Appl. (2013), WO 2013/074531 A1, 23 May 2013.
  18. Antihistamines combined with dietary supplements for improved health.  Knutsen, L.J.S.; Knutsen, J.L. (Discovery Pharma Consulting LLC). U.S. Pat. Appl. Publ. (2012), 20120170883 A1, December 13, 2012.
  19. Pyridazinone Derivatives. Bacon, E.R.; Bailey, T.R.; Becknell, N.C.; Chatterjee, S.; Dunn, D.; Hostetler, G.A.; Hudkins, R.L.; Josef, K.A.; Knutsen, L.J.S.; Tao, M.;  Zulli, A.L. (Cephalon, Inc.). U.S. Pat. Appl. Publ. (2011), 20110288075 A1, November 24 2011.
  20. Substituted pyridazine derivatives. Hudkins, R.L.; Knutsen, L.J.S.; Prouty, C.P.; Sundar, B.G.; Wells-Knecht, K.J. (Cephalon, Inc.). U.S. Pat. Appl. Publ. (2010), 20100311752 A1, December 9 2010.
  21. Pyridazinone Derivatives. Bacon, E.R.; Bailey, T.R.; Becknell, N.C.; Chatterjee, S.; Dunn, D.; Hostetler, G.A.; Hudkins, R.L.; Josef, K.A.; Knutsen, L.J.S.;  Tao, M.;  Zulli, A.L. (Cephalon, Inc.). U.S. Pat. Appl. Publ. (2010), US 20100280007 A1, 4 November 2010.
  22. Pyridazinone Derivatives. Bacon, E.R.; Bailey, T.R.; Becknell, N.C.; Chatterjee, S.; Dunn, D.; Hostetler, G.A.; Hudkins, R.L.; Josef, K.A.; Knutsen, L.J.S.;  Tao, M.;  Zulli, A.L. (Cephalon, Inc.). U.S. Pat. Appl. Publ. (2010), US 20100273779 A1, 28 October 2010.
  23. Substituted pyridazine derivatives which have histamine H3 antagonist activity.  Hudkins, R.L.; Knutsen, L.J.S.; Prouty, C.P.; Sundar, B.G.; Wells-Knecht, K.J. (Cephalon, Inc.). PCT Int. Appl. (2009), WO 09/97306 A1, 6 August 2009.
  24. Azacyclic compounds as inhibitors of sensory neuron specific channels (SNS). Hamlyn, R.; Huckstep, M.; Earnshaw, C.G.; Stokes, S.; Tickle, D.; Allart, B.; Boyd, J.W.; Knutsen, L.J.S.; Lynch, R.; Patient, L. (Ionix Pharmaceuticals Limited, UK). PCT Int. Appl. (2006), WO 06/082354 A1, 8 August 2006.
  25. Preparation of acyclic sulfonamides as N-type calcium channel antagonists. Hobbs, C.J.; Lynch, R.; Mellor, S.L.; Radford, F.; Gilbert, J.C.; Stokes, S.; Glen, A.; Fiumana, A.; Earnshaw, C.G.; Knutsen, L.J.S.; Dean, K.E.S. (Ionix Pharmaceuticals Limited, UK). PCT Int. Appl.  (2006), WO 06/030211 A2 23 March 2006.
  26. Sulfonamides, particularly N-(phenylsulfonyl)piperidines, as N-type calcium channels antagonists useful for treatment of pain and their preparation. Radford, F.; Lynch, R., Mellor, S. L.; Hobbs, C.J.; Gilbert, J.C.; Stokes, S.; Glen, A.; Fiumana, A.; Smith, N.J; Earnshaw, C.G.; Knutsen, L.J.S. (Ionix Pharmaceuticals Limited, UK).  PCT Int. Appl.  (2005), WO 05/068448 A1 28 July 2005.
  27. Preparation of benzene and phenol derivatives as inhibitors of sensory neuron specific (SNS) sodium channels. Jennings, N.S.; Stokes, S.; Hamlyn, R.J.; Tickle, D.C.; Huckstep, M. R.; Lynch, R.; Knutsen, L.J.S. (Ionix Pharmaceuticals Limited., UK). PCT Int. Appl. (2005), WO 05/00309 A2 06 January 2005.
  28. 1,3-Thiazolin-4-ones as therapeutic compounds in the treatment of pain.  Knutsen, L.J.S; Hobbs, C.J.; Radford, F.; Fiumana, A. (Ionix Pharmaceuticals Limited, UK). PCT Int. Appl. (2004) WO 04/17965 A1 04 March 2004.
  29. Five-membered heterocyclic compounds in the treatment of chronic and acute pain.  Knutsen, L.J.S.; Hobbs, C.J.; Radford, F.; Fiumana, A.; Earnshaw, C.G.; Mellor, S.L.; Smith, N.J. (Ionix Pharmaceuticals Limited, UK). PCT Int. Appl. (2004), WO 04/17966 A1 04 March 2004.
  30. Preparation of 4-quinolinemethanol derivatives as purine receptor antagonists. (II).  Gillespie, R. J.; Lerpiniere, J.; Giles, P.R.; Adams, D.R.; Knutsen, L.J.S.; Cliffe, I.A. (Cerebrus Ltd. UK) PCT Int. Appl.  (2000), 73 pp.  WO 00/13682 A2, 16 March 2000.
  31. Preparation of 4-quinolinemethanol derivatives as purine receptor antagonists. Gillespie, R.J.; Lerpiniere, J.; Gaur, S.; Adams, D.R.; Knutsen, L.J.S.; Ward, S.E. (Cerebrus Ltd. UK) PCT Int. Appl.  (2000), 76 pp.  WO 00/13681 A2, 16 March 2000.
  32. Novel pyridine and pyrimidine derivatives.  Knutsen, L.J.S.; Lundemose, A.G.; Jeppesen, C.B.; Sorensen, A.R.; Danielsen, G.M. (Novo Nordisk A/S, Den.) WO 99/31098 A1, June 24, 1999.
  33. (-)-Mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders.  Shepherd, R.; Knutsen, L.J.S.; Porter, R.H.P.; Weiss, S.M. (Cerebrus Ltd. UK) WO 99/26627, 03 June 1999.
  34. Preparation of novel halo-N-[(heterocyclyl)thio-1-piperidinyl]adenosines as A1 receptor agonists.  Knutsen, Lars.  (Novo Nordisk A/S, Den.)  WO 9816539 A1, 23 April 1998.
  35. Prepn. of nucleosides for treating disorders related to cytokines in mammals.  Knutsen, L.; Olsen, U.B.; Bowler, A.N. (Novo Nordisk A/S, Den.). PCT Int. Appl., 78 pp. WO 97/33591A1 18 Sept 1997.
  36. Preparation of N-alkoxyadenosines as cytokine inhibitors.  Knutsen, L.; Olsen, U.B.; Roberts, S.M.; Varley, D.R.; Bowler, A.N. (Novo Nordisk A/S, Den.). PCT Int. Appl., 70 pp. WO 98/01459 A1 15 January 1998.
  37. Preparation of novel halo-N-[(heterocyclyl)thio-1-piperidinyl]adenosines as A1 receptor agonists.  Knutsen, L. (Novo Nordisk A/S, Den.) WO 98/16539 A1, 23 April 1998.
  38. Preparation of adenosine derivatives for treatment of central nervous system diseases.  Lau, J.; Knutsen, L.J.S. (Novo Nordisk A/S, Den.). PCT Int. Appl., 62 pp.  WO 95/07921 A1 23 March 1995.
  39. Preparation of N-(heterocyclylalkyl)purine derivatives as adenosine A1 agonists. Lau, J.; Knutsen, L.J.S.; Sheardown, M.; Hansen, A.J. (Novo Nordisk A/S, Den.).  PCT Int. Appl., 68 pp.  WO 94/14832 A1 7 July 1994.
  40. Purine derivatives. Knutsen, L.J.S; Lau, J. (Novo Nordisk A/S, Den.). PCT Int. Appl., 49 pp. WO 93/23418 A1 25 November 1993.
  41. Adenosine derivatives.  Knutsen, L.J.S.; Lau, J. (Novo Nordisk A/S, Den.). PCT Int. Appl., 39 pp. WO 93/23417 A1 25 November 1993.
  42. Preparation of 2,6-disubstituted purine nucleoside anticonvulsants.  Knutsen, L.J.S; Lau, J. (Novo Nordisk A/S, Den.). PCT Int. Appl., 51 pp. WO 93/08206 A1 29 May 1993.
  43. Novel heterocyclic carboxylic acids. Andersen, K.E; Knutsen, L.J.S; Soerensen, P.O; Lundt, B.F.; Lau, J.; Petersen, H. (Novo Nordisk A/S, Den.). PCT Int. Appl., 58 pp. WO 92/20658 A1 26 November 1992.
  44. Preparation of N-[2-(3,3-diphenylpropoxy)ethyl]piperidine-3-carboxylates and analogs as GABA uptake inhibitors.  Andersen, K.E; Knudsen, L.J.S; Sonnewald, U.; Soerensen, P.O. (Novo-Nordisk A/S, Den.).  PCT Int. Appl., 63 pp.  WO 9107389 A1 30 May 1991
  45. Preparation of N-(aralkoxyalkyl)piperidinecarboxylates and analogs as GABA-uptake inhibitors.  Knutsen, L.J.S; Jorgensen, A.S; Andersen, K.E; Sonnewald, U. (Novo-Nordisk A/S, Den.). Eur. Pat. Appl., 25 pp.  EP 374801 27 June 1990.
  46. Azacyclic carboxylic acid derivatives, their preparation and use as GABAergic agonist pharmaceuticals.  Knutsen, L.J.S.; Andersen, K.E; Jorgensen, A.S; Sonnewald, U. (Novo Industri A/S, Den.).  Eur. Pat. Appl., 26 pp.  EP 342635 A1 23 November 1989.
  • Of these patents and patent applications, 25 are issued in the USA:
  1. US 10,385,028 Compounds for the Treatment of Neuromuscular Disorders
  2. US 9,700,548 Antihistamines Combined with Dietary Supplements for Improved Heath
  3. US 8,673,916 Methods of Treating Disorders Mediated by Histamine H3 receptors using Pyridazinone Derivatives
  4. US 8,586,588 Aryl Pyridazinone Derivatives and their use as H3 receptor ligands
  5. US 8,247,414 Pyridizinone derivatives and the use thereof as H3 inhibitors
  6. US 8,207,168 Pyridazinone derivatives
  7. US 8,076,331 Substituted Pyridazine derivatives
  8. US 6,608,085 4-Quinolinemethanol derivatives as purine receptor antagonists (II)
  9. US 6,583,156 4-Quinolinemethanol derivatives as purine receptor antagonists (I)
  10. US 6,197,788 (-)-Mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
  11. US 5,683,989 Treatment of ischemias by administration of 2,N.sup.6 -substituted adenosines
  12. US 5,672,588 Purine derivatives
  13. US 5,589,467 2,5′,N6-trisubstituted adenosine derivatives
  14. US 5,578,582 Methods of treating ischemia with C2, N6 -disubstituted adenosine derivatives
  15. US 5,484,774 2, N6 -disubstituted adenosines, tri-O-ester derivatives and their pharmaceutical compositions to treat ischemias
  16. US 5,432,164 C2,N6 -disubstituted adenosine derivatives
  17. US 5,430,027 2-Chloro-N6 -substituted adenosines, their pharmaceutical compositions, and activity in treating ischemias
  18. US 5,348,965 N-substituted azaheterocyclic carboxylic acids
  19. US 5,231,106 Azacyclic carboxylic acid derivatives and their preparation and use
  20. US 5,229,404 Azacyclic carboxylic acid derivatives and their preparation and use
  21. US 5,214,057 N-substituted azaheterocyclic carboxylic acids
  22. US 5,214,054 Azacyclic carboxylic acid derivatives and their preparation and use
  23. US 5,198,451 Heterocyclic carboxylic acids
  24. US 5,071,859 N-substituted azaheterocyclic carboxylic acids and pharmaceutical uses
  25. US 5,039,685 Azacyclic carboxylic acid derivatives, their preparation and use

Leave a Reply

Your email address will not be published. Required fields are marked *